Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop via mTORC2. Vistusertib, a dual inh...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Schmid, Peter, Zaiss, Matthias, Harper-Wynne, Catherine, Ferreira, Marta, Dubey, Sidharth, Chan, Stephen, Makris, Andreas, Nemsadze, Gia, Brunt, Adrian M., Kuemmel, Sherko, Ruiz, Isabel, Perelló, Antonia, Kendall, Anne, Brown, Janet, Kristeleit, Hartmut, Conibear, John, Saura, Cristina, Grenier, Julien, Máhr, Károly, Schenker, Michael, Sohn, Joohyuk, Lee, Keun Seok, Shepherd, Christopher J., Oelmann, Elisabeth, Sarker, Shah-Jalal, Prendergast, Aaron, Marosics, Patricia, Moosa, Atiyyah, Lawrence, Cheryl, Coetzee, Carike, Mousa, Kelly, Cortés, Javier
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865233/
https://ncbi.nlm.nih.gov/pubmed/31465093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.2526
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi